Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: Effects of adverse prognostic factors on outcome

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 1, 2011, Pages 44-49

  Bladé, Joan ^a   Sonneveld, Pieter ^b   San Miguel, Jesús F ^c   Sutherland, Heather J ^d   Hajek, Roman ^e   Nagler, Arnon ^f   Spencer, Andrew ^g   Robak, Tadeusz ^h   Lantz, Keith C ⁱ   Zhuang, Sen H ^j   Harousseau, Jean Luc ^k   Orlowski, Robert Z ^l  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CSIC   (Spain)

^d Leukemia Bone Marrow Transplant Program of British Columbia   (Canada)

^e UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^f SHEBA MEDICAL CENTER   (Israel)

^g ALFRED HOSPITAL   (Australia)

^h MEDICAL UNIVERSITY OF LODZ   (Poland)

ⁱ CENTOCOR INC   (United States)

^j JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^k HÔTEL DIEU   (France)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Clinical outcomes; Multiple myeloma; Relapsed refractory disease

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DOXORUBICIN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER GROWTH; CANCER RESISTANCE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GROUPS BY AGE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PROGNOSIS; RETROSPECTIVE STUDY; STOMATITIS; THROMBOEMBOLISM; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; POLYETHYLENE GLYCOLS; PROGNOSIS; PYRAZINES; RETROSPECTIVE STUDIES;

EID: 79953715170     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2011.n.005     Document Type: Article

References (18)

1. Blade J, Rosinol L, Cibeira MT. Prognostic factors for multiple myeloma in the era of novel agents. Ann Oncol 2008; 19(suppl 7):vii117-20.
2. Fonseca R, San MJ. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am 2007; 21:1115-40 ix. (Pubitemid 350064355)
3. Rajkumar SV, Buadi F. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol 2007; 20:665-80. (Pubitemid 350215386)
4. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79:867-74. (Pubitemid 38879952)
5. Greipp PR, San MJ, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412-20.
6. Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81:3382-7. (Pubitemid 23172924)
7. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007; 137:429-35. (Pubitemid 46698286)
8. Hussein MA, Wood L, Hsi E, et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002; 95:2160-8. (Pubitemid 35253378)
9. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98. (Pubitemid 41007864)
10. Rifkin RM, Gregory SA, Mohrbacher A, et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 2006; 106:848-58. (Pubitemid 43238452)
11. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25:3892-901. (Pubitemid 47477266)
12. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105:3058-65.
13. Biehn SE, Moore DT, Voorhees PM, et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2007; 86:211-6. (Pubitemid 46195994)
14. Blade J, Sonneveld P, San Miguel JF, et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 2008; 8:352-5.
15. Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008; 112:1529-37. (Pubitemid 351441165)
16. Barlogie B, Anaissie E, van RF et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.Br J Haematol 2007; 138:176-85. (Pubitemid 46978271)
17. Harousseau JL, Attal M, Moreau P, et al. Should CR achievement be a major treatment objective? Haematologica 2007; 92:36-7
18. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110:3557-60. (Pubitemid 350159621)